# A Study to Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide in Subjects With Refractory or Relapsed Non-Hodgkin's Ly

Source: https://onco.cc/trials/nct05950165/  
OnCo record `nct05950165` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Lenalidomide in hodgkin lymphoma and non-hodgkin lymphoma, run by Cho Pharma Inc., active and no longer recruiting.

## Summary

A Study to Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide in Subjects With Refractory or Relapsed Non-Hodgkin's Lymphoma is a phase 1/2 interventional study registered as NCT05950165 by Cho Pharma Inc., with 37 participants planned, started 2020-01-15 and due to reach its primary completion in 2026-12-23. Interventions recorded: CHO-H01, CHO-H01 at RP2D, Lenalidomide. Conditions listed: Non-Hodgkin Lymphoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05950165
- Phase: 1/2
- Setting: A Phase I/IIa, Open-label, Multicenter Study of the Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide to Subjects With Refractory or Relapsed Non-Hodgkin's Lymphoma
- Sponsor: Cho Pharma Inc.
- Enrolled: 37

## Sources

- ClinicalTrials.gov NCT05950165: https://clinicaltrials.gov/study/NCT05950165

## Connected records

- cancers: [Hodgkin lymphoma](https://onco.cc/cancers/hodgkin-lymphoma/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- drugs: [Lenalidomide](https://onco.cc/drugs/lenalidomide/)

---
JSON: https://onco.cc/api/v1/entities/nct05950165.json